Xerox has unveiled an accreditation program that offers extensive support for the vendor's top managed print services (MPS) partners as it looks to bring more of that business to the channel.

Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks ...